JUL 26, 2016 05:40 AM PDT

Certain Colon Cancer Can be 'Starved' to Death

WRITTEN BY: Xuan Pham

Colon cancer is the third most common non-skin cancer type in the U.S. Now researchers say they have gained a huge advantage in discovering the key compound that sustains a large portion of these cancers. By blocking the compound, researchers showed significant tumor reduction. The findings are so promising that clinical trials for colorectal cancer patients will be starting this August at the University Hospitals Seidman Cancer Center.
 


Approximately over 1 million Americans are diagnosed with colorectal cancer, also known as colon cancer. Of these cases, about a third are due to mutations in a gene known as PIK3CA, which is involved in critical cell signaling processes such as cell growth and division, migration, and survival. Mutations in this gene are also responsible for a host of other cancer types, including lung cancer, breast and ovarian cancer, and head and neck cancer.

In studying colon cancer cells with PIK3CA mutations, the team at Case Western Reserve noted a very specific pattern of metabolism. In particular, they found that cells with PIK3CA mutations broke down the amino acid glutamine at a significantly faster pace than cells without the mutation. The increased need for glutamine stemmed from cancer cells’ overactive enzyme activities. Thus, glutamine is necessary in the colon cancer cells’ survival.

“We discovered that colon cancers with PIK3CA oncogenic mutations are addicted to glutamine, a particular nutrient for cancer cells. We also demonstrated that these cancers can be starved to death by depriving glutamine with drugs," said Zhenghe John Wang, professor of genetics and genome sciences and co-leader of the Cancer Genetics Program at Case Western Reserve University, and senior author of the study.
 

Image credit: Pixabay.com

Indeed, when the team starved mutant cells of glutamine, they observed more cell death. Even more promising, when they reduced glutamine levels in mice with colon cancer, they saw slower and smaller tumor growths. The same treatment in cancer cells without the PIK3CA mutation were not effective, indicating a specific link between PIK3CA and glutamine.

Glutamine is a non-essential (or conditional) amino acid that can be made by the body under the appropriate conditions. Its levels can be easily modulated with glutamine blockers, making treatment relatively straightforward. Furthermore, because PIK3CA is a well-known player in many other types of cancer makes the results are broadly appealing. As such, Phase I/II clinical trials stemming from this study are already planned for this later this summer.

"This study provides the basis for a colon cancer treatment clinical trial that will be started in the summer at the University Hospitals Seidman Cancer Center," according to Neal Meropol, chief of the division of hematology and oncology, and lead investigator for the trial.

Additional source: Case Western Reserve University materials via EurekAlert!

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 17, 2019
Cancer
OCT 17, 2019
Self-Destructing Cancer: Study Stops Chain Reaction of Tumor Growth
A new study reveals that stopping one protein from functioning can cause some cancer cells to die from stress....
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Anti-cancer Drug Disguises as Fat
According to a study published in the Journal of the American Chemical Society (JACS), a new drug-delivery system disguises as fat in order to outsmart tum...
OCT 17, 2019
Cancer
OCT 17, 2019
New hope for metastatic cancer treatment
New research recently published in the journal iScience takes a deeper look into metastatic cancers, finding that a particular gene called mEAK-7 may play ...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Aspirin: The Good and Bad for Breast Cancer Survivors
Early research has indicated that aspirin usage may increase the survival rate among women with breast cancer. These studies were based on aspirin’s ...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Compound in Daffodils Can Help Fight Cancer
Preventing the growth of tumors presents a challenge for scientists in finding a cure to cancer. Now however, researchers from the University Libre de Brux...
OCT 17, 2019
Genetics & Genomics
OCT 17, 2019
A Cancer-Promoting Mutation is Found in 'Junk' DNA
A huge amount of our genome does not code for protein, but it can impact physiology in other ways....
Loading Comments...